TABLE 3.
Synergistic activity of fosfomycin in combination with other antibiotics against several clinically relevant bacteria
| Organism(s) | Antibiotics with activity in combination with fosfomycin (reference[s]) |
||
|---|---|---|---|
| Synergy | Indifference | Antagonism | |
| MSSA | Linezolid (174), ciprofloxacin (24), ceftriaxone (137), ciprofloxacin (137), rifampin (137) | Vancomycin (137), ceftriaxone (137), gentamicin (137) | |
| MRSA | Cefamandole (138, 139, 268), cefazolin (138, 139, 268), vancomycin (29, 137, 229), rifampin (29, 90, 142, 147), carbapenems (13, 152), cefmetazole (13), cefoperazone-sulbactam (13), linezolid (161), quinupistin-dalfopristin (162), fusidic acid (90), minocycline (163), tigecycline (29), daptomycin (29, 165) | Aminoglycosides (268), fusidic acid (268), trimethoprim (268), vancomycin (137) | Rifampin (139) |
| Glycopeptide-intermediate S. aureus | Imipenem (166), vancomycin (166), linezolid (166) | ||
| CoNS | Ciprofloxacin (137), imipenem (137), rifampin (137) | Vancomycin (137) | |
| MR S. epidermidis | Vancomycin (167) | ||
| Enterococcus | Cefotaxime (137), daptomycin (137),a imipenem (137)a | ||
| VRE | Daptomycin (36), teicoplanin (92), amoxicillin (36), linezolid (36, 92),b ampicillin (92),b vancomycin (92),a tigecycline (92),a rifampin (92)a | Nitrofurantoin (92), minocycline (92) | Ampicillin (92) |
| Streptococcus spp. | Penicillin (137),a cefminox (137),a cefotaxime (137)a | Vancomycin (137), imipenem (137), ceftriaxone (137), cefepime (137) | |
| E. coli | Gentamicin (137)a | ||
| ESBL-producing E. coli | Carbapenems (84),a aztreonam (153),colistin (84),b aminoglycosides (28, 84),a tigecycline (28, 84),a colistin (28) | ||
| ESBL-producing K. pneumoniae | Carbapenems (84), colistin (84),b netilmicin (84),a tigecycline (84)a | ||
| K. pneumoniae | Gentamicin (137)a | ||
| MDR K. pneumoniae | Carbapenem (152), aztreonam (153) | ||
| CR K. pneumoniae | Carbapenems (84, 164, 179), colistin (84, 164, 179),a tigecycline (84),a netilmicin (84)a | Gentamicin (179) | Colistin (156), (OXA-48-producing strain) |
| NDM-1-producing Enterobacteriaceae | Colistin (158), tigecycline (158) | ||
| Salmonella | Amilacin (137),a cefepime (137) | ||
| P. aeruginosa | Aztreonam (137),a levofloxacin (137),a ciprofloxacin (137),a cefepime (137),a gentamicin (137),a piperacillin (137),a ceftazidime (137),a imipenem (137)a | Imipenem (137), ceftazidime (137), ciprofloxacin (137), gentamicin (137) | |
| CR P. aeruginosa | Colistin (149),a carbapenems (149, 150),a aminoglycosides (27, 40), piperacillin-tazobactam (40), ceftazidime (40), cefepime (40), ciprofloxacin (40) | ||
| MDR P. aeruginosa | Carbapenems (84), colistin (189),b tigecycline (84),b netilmicin (84)b | Carbapenems (152), aminoglycosides (168) | |
| Acinetobacter | Amikacin (137)a | Imipenem (137), ceftazidime (137), ciprofloxacin (137) | |
| OXA-23-producing Acinetobacter | Colistin (59, 89),a,b sulbactam (89) | ||
| Pan-drug-resistant Acinetobacter | Polymyxin B (90),b minocycline (90)b | ||
| N. gonorrhoeae | Ceftriaxone (44) | Cefixime (159, 253), ceftriaxone (159, 253), azithromycin (253), colistin (253), ertapenem (253), gentamicin (253), minocycline (253), oxifloxacin (253) | |
a
Synergy was observed in ≤50% of tested strains.
b
Synergy was observed in <20% of tested strains.